These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 28353583

  • 1. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.
    Noreikaitė A, Saint-Marcoux F, Marquet P, Kaduševičius E, Stankevičius E.
    Medicine (Baltimore); 2017 Mar; 96(13):e6469. PubMed ID: 28353583
    [Abstract] [Full Text] [Related]

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE.
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [Abstract] [Full Text] [Related]

  • 4. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
    Tedesco-Silva H, Felipe CR, Slade A, Schmouder RL, Medina Pestana JO.
    Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
    [Abstract] [Full Text] [Related]

  • 5. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [Abstract] [Full Text] [Related]

  • 6. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y.
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
    El Haggan W, Ficheux M, Debruyne D, Rognant N, Lobbedez T, Allard C, Coquerel A, Ryckelynck JP, Hurault de Ligny B.
    Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.
    Clin Chem; 2001 Apr; 47(7):1241-8. PubMed ID: 11427455
    [Abstract] [Full Text] [Related]

  • 12. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients.
    Filler G, Lepage N, Delisle B, Mai I.
    Ther Drug Monit; 2001 Oct; 23(5):514-9. PubMed ID: 11591896
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M, Gotti E, Pradini S, Gaspari F, Perico N.
    Transplantation; 2011 Sep 15; 92(5):550-6. PubMed ID: 21709602
    [Abstract] [Full Text] [Related]

  • 15. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb 15; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 16. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K.
    Transplant Proc; 2004 Sep 15; 36(7):2076-8. PubMed ID: 15518751
    [Abstract] [Full Text] [Related]

  • 17. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation.
    Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti E, Remuzzi G, Perico N.
    Am J Transplant; 2005 Dec 15; 5(12):2937-44. PubMed ID: 16303008
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.
    Liver Transpl; 2007 Nov 15; 13(11):1570-5. PubMed ID: 17969194
    [Abstract] [Full Text] [Related]

  • 20. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.
    Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y.
    Clin Ther; 2008 Apr 15; 30(4):673-83. PubMed ID: 18498916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.